Product news from the 11/04/05 News Brief

Share this article:

Novartis announced the FDA's approval of Exjade (deferasirox), a once-daily oral iron chelator designed to treat chronic iron overload due to blood transfusions in adults and children ages two and older.

Roche's Tarceva (erlotinib), has won FDA approval for treatment of advanced pancreatic cancer.

Savient Pharmaceuticals announced the FDA approval of its New Drug Application for Soltamox (tamoxifen oral solution) for the treatment of breast cancer in adjuvant and metastatic settings and to reduce risks of breast cancer in women with ductal carcinoma in situ (DCIS) and reduction of breast cancer incidence in women with high risk of breast cancer. Soltamox is the product of Savient's wholly owned subsidiary, Rosemont Pharmaceuticals Ltd., located in the U.K.

GlaxoSmithKline announced that the FDA has approved Arranon (nelarabine) Injection, a chemotherapy agent for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and Tcell lymphoblastic lymphoma (TLBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Share this article:

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.